Trial · NCT05019430
Cocaine and Zolmitriptan
NCT05019430, Early phase 1, Completed, William Stoops; results first posted 2025-08-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cocaine and Zolmitriptan. Trials, record NCT05019430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05019430
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cocaine and Zolmitriptan
- NCT number
- NCT05019430
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 12 participants, actual
- Lead sponsor
- William Stoops
- Conditions
- Cocaine Use Disorder
- Interventions
- Cocaine, Placebo oral capsule, Zolmitriptan
- First posted
- 2021-08-24
- Last updated
- 2025-08-05
- Results first posted
- 2025-08-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reinforcing Effects of Cocaine | Over approximately four hours on each experimental session day, which generally occurred on Days 5-7, 13-15, 21-23 and 29-31 of inpatient admission. | Number of Times Subjects Choose Cocaine (Maximum of 5 Choices) Over Money |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reinforcing Effects of Cocaine | Over approximately four hours on each experimental session day, which generally occurred on Days 5-7, 13-15, 21-23 and 29-31 of inpatient admission. | Subjects completing the dose condition | number of times subjects chose cocaine | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reinforcing Effects of Cocaine | Dose Condition 1 | 1.4 | Standard Deviation 1.96 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 2 | 4 | Standard Deviation 1.61 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 3 | 4.5 | Standard Deviation 1.51 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 4 | 0.7 | Standard Deviation 1.57 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 5 | 3.6 | Standard Deviation 2.06 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 6 | 4.5 | Standard Deviation 1.58 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 7 | 0.6 | Standard Deviation 1.57 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 8 | 3.5 | Standard Deviation 1.97 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 9 | 4.6 | Standard Deviation 0.67 | number of times subjects chose cocaine | |
| Reinforcing Effects of Cocaine | Dose Condition 10 | 0.7 | Standard Deviation 1.42 | number of times subjects chose cocaine |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Overall Study | 12 | |
| Overall Study | Dose Condition 1 | Overall Study | 9 | |
| Overall Study | Dose Condition 2 | Overall Study | 10 | |
| Overall Study | Dose Condition 3 | Overall Study | 10 | |
| Overall Study | Dose Condition 4 | Overall Study | 10 | |
| Overall Study | Dose Condition 5 | Overall Study | 10 | |
| Overall Study | Dose Condition 6 | Overall Study | 10 | |
| Overall Study | Dose Condition 7 | Overall Study | 11 | |
| Overall Study | Dose Condition 8 | Overall Study | 11 | |
| Overall Study | Dose Condition 9 | Overall Study | 11 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events120
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Tachycardia | Cardiac disorders | Zolmitriptan (0 mg/Day) | 5 | 10 | |
| other | Tachycardia | Cardiac disorders | Zolmitriptan (2.5 mg/Day) | 4 | 10 | |
| other | Tachycardia | Cardiac disorders | Zolmitriptan (5 mg/Day) | 3 | 11 | |
| other | Tachycardia | Cardiac disorders | Zolmitriptan (10 mg/Day) | 5 | 11 | |
| other | Hypertension | Cardiac disorders | Zolmitriptan (0 mg/Day) | 4 | 10 | |
| other | Hypertension | Cardiac disorders | Zolmitriptan (2.5 mg/Day) | 4 | 10 | |
| other | Hypertension | Cardiac disorders | Zolmitriptan (5 mg/Day) | 6 | 11 | |
| other | Hypertension | Cardiac disorders | Zolmitriptan (10 mg/Day) | 7 | 11 | |
| other | Deviated Midline Catheter | Surgical and medical procedures | Zolmitriptan (0 mg/Day) | 2 | 10 | |
| other | Deviated Midline Catheter | Surgical and medical procedures | Zolmitriptan (2.5 mg/Day) | 0 | 10 |
1 to 10 of 120Source ClinicalTrials.gov
See all 120 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zolmitriptan (0 mg/Day) | 0 | 10 |
| Total, all-cause mortality | Zolmitriptan (2.5 mg/Day) | 0 | 10 |
| Total, all-cause mortality | Zolmitriptan (5 mg/Day) | 0 | 11 |
| Total, all-cause mortality | Zolmitriptan (10 mg/Day) | 0 | 11 |
| Total, other adverse events | Zolmitriptan (0 mg/Day) | 10 | 10 |
| Total, other adverse events | Zolmitriptan (2.5 mg/Day) | 10 | 10 |
| Total, other adverse events | Zolmitriptan (5 mg/Day) | 11 | 11 |
| Total, other adverse events | Zolmitriptan (10 mg/Day) | 11 | 11 |
| Total, serious adverse events | Zolmitriptan (0 mg/Day) | 1 | 10 |
| Total, serious adverse events | Zolmitriptan (2.5 mg/Day) | 0 | 10 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA052203 | Influence of 5-HT1b Activation on the Abuse Related Effects of Cocaine | STOOPS, WILLIAM WALTON | UNIVERSITY OF KENTUCKY | NATIONAL INSTITUTE ON DRUG ABUSE | 2021 to 2022 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05019430
GET https://conductscience.org/api/trials/v1/NCT05019430/events?page=2